Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial-Reference-Cited by-同舟云学术

Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial

Published:2021-11 Issue: Volume:41 Page:101152
ISSN:2589-5370
Container-title:EClinicalMedicine
language:en
Short-container-title:EClinicalMedicine

Author:

Tornling Göran,Batta Rohit,Porter Joanna C.^ORCID,Williams Bryan,Bengtsson Thomas,Parmar Kartikeya,Kashiva Reema,Hallberg Anders,Cohrt Anne Katrine,Westergaard Kate,Dalsgaard Carl-Johan,Raud Johan^ORCID

Funder

UCLH Biomedical Research Centre

LifeArc

Publisher

Elsevier BV

Subject

General Medicine

Reference40 articles.

1. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding;Lu;Lancet,2020

2. A new coronavirus associated with human respiratory disease in China;Wu;Nature,2020

3. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study;Zhou;Lancet,2020

4. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study;Chen;Lancet,2020

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Microvascular angiotensin II type 2 receptor function is enhanced in young females and declines in a model of murine aging;The Journal of Cardiovascular Aging;2024-08-15

2. Anti-inflammatory therapy with nebulized dornase alfa for severe COVID-19 pneumonia: a randomized unblinded trial;eLife;2024-07-16

3. Alternative Renin-Angiotensin System;Hypertension;2024-05

4. Anti-inflammatory therapy with nebulised dornase alfa for severe COVID-19 pneumonia;2024-05-01

5. Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial;eClinicalMedicine;2024-01